<DOC>
	<DOCNO>NCT00362427</DOCNO>
	<brief_summary>PR5I , hexavalent pediatric combination vaccine develop reduce number injection first 2 year life provide complete course immunization infection cause H. influenzae type b , hepatitis B virus , Corynebacterium diphtheriae , Clostridium tetani , Bordetella pertussis , poliovirus type 1 , 2 , 3 . Primary Objective : To evaluate immunogenicity PR5I adjuvant composition enhancement hepatitis B component administer concomitantly Prevnar® Secondary Objectives : To assess safety immunogenicity PR5I administer concomitantly , one month apart Prevnar® separately license vaccine use routine infant vaccination Canada .</brief_summary>
	<brief_title>Study PR5I , Pediatric Combination Vaccine With Enhanced Hepatitis B Component Given Concomitantly With Prevnar®</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Heptavalent Pneumococcal Conjugate Vaccine</mesh_term>
	<criteria>Infants age 42 89 day inclusive day inclusion . Born full term pregnancy ( &gt; 37 week ) . Informed consent form sign parent ( ) legally authorize representative . Able attend schedule visit comply study procedure . Parent legally authorize representative access telephone . Parent legally authorize representative able read write English French . Participation another clinical trial 4 week precede first trial vaccination . Planned participation another clinical trial present trial period . Personal immediate family history congenital acquire immunodeficiency , immunosuppressive therapy longterm systemic corticosteroid therapy . Known suspected systemic hypersensitivity vaccine component history lifethreatening reaction vaccine contain substance trial vaccine ( ) . Chronic illness could interfere trial conduct completion . Received blood bloodderived product since birth . Any vaccination precede first trial vaccination plan 4 week trial vaccination ( flu vaccine may give minimum 4 week prior first study vaccination ) . Previous vaccination acellular pertussis ( DTaP ) whole cell pertussis ( DTwP ) base combination vaccine , Haemophilus influenzae type b ( Hib ) conjugate , poliovirus , hepatitis B , pneumococcal conjugate vaccine . Coagulation disorder contraindicate IM vaccination . Clinically significant finding review system ( determined investigator subinvestigator sufficient exclusion ) . Developmental delay neurological disorder . Any condition , opinion investigator , would interfere evaluation vaccine pose health risk subject . Documented Hepatitis B surface Antigen ( HBsAg ) seropositivity child his/her mother . History Hib , hepatitis B , diphtheria , tetanus , pertussis poliovirus disease .</criteria>
	<gender>All</gender>
	<minimum_age>42 Days</minimum_age>
	<maximum_age>89 Days</maximum_age>
	<verification_date>January 2014</verification_date>
	<keyword>Hepatitis B</keyword>
	<keyword>Pertussis</keyword>
	<keyword>Diphtheria</keyword>
	<keyword>Tetanus</keyword>
	<keyword>H. influenzae type b</keyword>
	<keyword>Polio</keyword>
</DOC>